dm pada anak

51
UPDATE ON CHILDHOOD UPDATE ON CHILDHOOD DIABETES MELLITUS DIABETES MELLITUS Abdelaziz Elamin MD, PhD, FRCPCH Professor of Child Health Sultan Qaboos University

description

book

Transcript of dm pada anak

Page 1: dm pada anak

UPDATE ON UPDATE ON CHILDHOOD CHILDHOOD

DIABETES MELLITUSDIABETES MELLITUS

Abdelaziz Elamin MD, PhD, FRCPCH Professor of Child

HealthSultan Qaboos

University

Page 2: dm pada anak

DEFINITION

The term diabetes mellitus describes a metabolic disorder of multiple etiologies characterized by chronic hyperglycemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects of insulin secretion, insulin action or both.

Page 3: dm pada anak

DIABETES EPIDEMIOLOGY

Diabetes is the most common endocrine problem & is a major health hazard worldwide.

Incidence of diabetes is alarmingly increasing all over the globe.

Incidence of childhood diabetes range between 3-50/100,000 worldwide; in Oman it is estimated as 4/100000 per year.

Page 4: dm pada anak

OLD CLASSIFICATION (1985)

Type 1, Insulin-dependent (IDDM) Type 2, Non Insulin-dependent

(NIDDM)– obese– non-obese– MODY

IGT Gestational Diabetes

Page 5: dm pada anak

WHO CLASSIFICATION 2000

Is based on etiology not on type of treatment or age of the patient.

Type 1 Diabetes (idiopathic or autoimmune -cell

destruction) Type 2 Diabetes

(defects in insulin secretion or action) Other specific types

Page 6: dm pada anak

WHO CLASSIFICATION/2

Both type 1 & type 2 can be further subdivided into:Not insulin requiringInsulin requiring for controlInsulin requiring for survival

Gestational diabetes is a separate entity

Impaired Glucose Tolerance (IGT) indicates blood glucose levels between normal & diabetic cut off points during glucose tolerance test.

Page 7: dm pada anak

DIAGNOSTIC CRITERIA

Fasting blood glucose level

DiabeticPlasma >7.0 mmolCapillary >6.0

mmol

IGT Plasma 6.0-6.9 mmol Capillary 5.6-6.0

mmol

2 hours after glucose load

(Plasma or capillary BS)

IGT7.8-11.0

Diabetic level> 11.1 (200 mg)

Page 8: dm pada anak

Types of Diabetes in Children

Type 1 diabetes mellitus accounts for >90% of cases.

Type 2 diabetes is increasingly recognized in children with presentation like in adults.

Permanent neonatal diabetes Transient neonatal diabetes Maturity-onset diabetes of the young Secondary diabetes e.g. in cystic

fibrosis or Cushing syndrome.

Page 9: dm pada anak

MODY Usually affects older children &

adolescents Not rare as previously

considered 5 subclasses are identified, one

subclass has specific mode of inheritance (AD)

Not associated with immunologic or genetic markers

Insulin resistance is present

Page 10: dm pada anak

TRANSIENT NEONATAL DIABETES

Observed in both term & preterm babies, but more common in preterm

Caused by immaturity of islet -cells Polyuria & dehydration are prominent,

but baby looks well & suck vigorously Highly sensitive to insulin Disappears in 4-6 weeks

Page 11: dm pada anak

PERMANENT NEONATAL DIABETES

A familial form of diabetes that appear shortly after birth & continue for life

The usual genetic & immunologic markers of Type 1 diabetes are absent

Insulin requiring, but ketosis resistant

Is often associated with other congenital anomalies & syndromes e.g. Wolcott-Rallison syndrome.

Page 12: dm pada anak

TYPE 1 DIABETES: ETIOLOGY

Type 1 diabetes mellitus is an autoimmune disease.

It is triggered by environmental factors in genetically susceptible individuals.

Both humoral & cell-mediated immunity are stimulated.

Page 13: dm pada anak

GENETIC FACTORSEvidence of genetics is shown in Ethnic differencesFamilial clusteringHigh concordance rate in twinsSpecific genetic markersHigher incidence with genetic

syndromes or chromosomal defects

Page 14: dm pada anak

AUTOIMMUNITY Circulating antibodies against -cells

and insulin. Immunofluorescent antibodies &

lymphocyte infiltration around pancreatic islet cells.

Evidence of immune system activation. Circulating immune complexes with high IgA & low interferon levels.

Association with other autoimmune diseases.

Page 15: dm pada anak

ENVIRONMENTAL INFLUENCE

Seasonal & geographical variation. Migrants take on risk of new

home. Evidence for rapid temporal

changes. Suspicion of environmental agents

causing disease which is confirmed by case-control experimental animal studies.

Page 16: dm pada anak

ENVIRONMENTAL SUSPECTS

VirusesCoxaschie BMumpsRubellaReoviruses

Nutrition & dietary factorsCow’s milk proteinContaminated sea food

Page 17: dm pada anak

OTHER MODIFYING FACTORS

The counter-regulatory hormones:glucagoncortisol,catecholaminesthyroxin,GH & somatostatinsex hormones

Emotional stress

Page 18: dm pada anak

ETIOLOGIC MODEL The etiologic model of type 1

diabetes resembles that of Rheumatic fever.

Rheumatic fever was prevented by elimination of the triggering environ. factor (-streptococci).

Similarly type 1 diabetes may be prevented by controlling the triggering factors in high risk persons.

Page 19: dm pada anak

CLINICAL PRESENTATIONS

Classical symptom triad: polyuria, polydipsia and

weight lossDKAAccidental diagnosisAnorexia nervosa like

illness

Page 20: dm pada anak

DIAGNOSIS In symptomatic children a random

plasma glucose >11 mmol (200 mg) is diagnostic.

A modified OGTT (fasting & 2h) may be needed in asymptomatic children with hyperglycemia if the cause is not obvious.

Remember: acute infections in young non-diabetic children can cause hyperglycemia without ketoacidosis.

Page 21: dm pada anak

NATURAL HISTORY

Diagnosis & initiation of insulin

Period of metabolic recovery

Honeymoon phase

State of total insulin

dependency

Page 22: dm pada anak

METABOLIC RECOVERY

During metabolic recovery the patient may

Develop one or more of the following: •Hepatomegaly•Peripheral edema•Loss of hair•Problem with visual acuity

These are caused by deposition of glycogen & metabolic re-balance.

Page 23: dm pada anak

HONEYMOON PERIOD

Due to -cell reserve optimal function & initiation of insulin therapy.

Leads to normal blood glucose level without exogenous insulin.

Observed in 50-60% of newly diagnosed patients & it can last up to one year but it always ends.

Can confuse patients & parents if not educated about it early.

Page 24: dm pada anak

COMPLICATIONS OF DIABETES

Acute:DKAHypoglycemia

Late-onset:Retinopathy NeuropathyNephropathyIschemic heart disease &

stroke

Page 25: dm pada anak

TREATMENT GOALS

Prevent death & alleviate symptoms

Achieve biochemical control

Maintain growth & development

Prevent acute complications

Prevent or delay late-onset

complications

Page 26: dm pada anak

TREATMENT ELEMENTS

Education Insulin therapy Diet and meal planning Monitoring

HbA1c every 2-monthsHome regular BG monitoring Home urine ketones tests when

indicated

Page 27: dm pada anak

EDUCATION

Educate child & care givers about: Diabetes Insulin Life-saving skills Recognition of Hypo & DKA Meal plan Sick-day management

Page 28: dm pada anak

INSULIN

A polypeptide made of 2 -chains.

Discovered by Bants & Best in 1921.

Animal types (porcine & bovine) were used before the introduction of human-like insulin (DNA-recombinant types).

Recently more potent insulin analogs are produced by changing aminoacid sequence.

Page 29: dm pada anak

FUNCTION OF INSULIN

Insulin being an anabolic hormone stimulates protein & fatty acids synthesis.

Insulin decreases blood sugar 1. By inhibiting hepatic

glycogenolysis and gluconeogenesis.

2. By stimulating glucose uptake, utilization & storage by the liver, muscles & adipose tissue.

Page 30: dm pada anak

TYPES OF INSULIN

Short acting (neutral, soluble, regular)Short acting (neutral, soluble, regular)Peak 2-3 hours & duration up to 8 hours

Intermediate actingIntermediate acting Isophane (peak 6-8 h & duration 16-24 h)Biphasic (peak 4-6 h & duration 12-20 h)Semilente (peak 5-7 h & duration 12-18 h)

Long acting (lente, ultralente & PZI)Long acting (lente, ultralente & PZI)Peak 8-14 h & duration 20-36 h

Page 31: dm pada anak

INSULIN CONCENTRATIONS

Insulin is available in different

concentrations 40, 80 & 100 Unit/ml.

WHO now recommends U 100 to be the

only used insulin to prevent confusion.

Special preparation for infusion pumps

is soluble insulin 500 U/ml.

Page 32: dm pada anak

INSULIN REGIMENS

Twice daily: either NPH alone or NPH+SI.

Thrice daily: SI before each meal and NPH only before dinner.

Intensive 4 times/day: SI before meals + NPH or Glargine at bed time.

Continuous s/c infusion using pumps loaded with SI.

Page 33: dm pada anak

INSULIN ANALOGS

Ultra short actingUltra short acting Insulin Lispro Insulin Aspart

Long acting without peak Long acting without peak action to simulate normal action to simulate normal basal insulinbasal insulin Glargine

Page 34: dm pada anak

NEW INSULIN PREPARATIONS

Inhaled insulin proved to be effective & will be available within 2 years.

Nasal insulin was not successful because of variable nasal absorption.

Oral insulin preparations are under trials.

Page 35: dm pada anak

ADVERSE EFFECTS OF INSULIN

Hypoglycemia Lipoatrophy Lipohypertrophy Obesity Insulin allergy Insulin antibodies Insulin induced edema

Page 36: dm pada anak

PRACTICAL PROBLEMS

Non-availability of insulin in poor countries

injection sites & technique Insulin storage & transfer Mixing insulin preparations Insulin & school hours Adjusting insulin dose at home Sick-day management Recognition & Rx of hypo at home

Page 37: dm pada anak

DIET REGULATION Regular meal plans with calorie

exchange options are encouraged. 50-60% of required energy to be

obtained from complex carbohydrates.

Distribute carbohydrate load evenly during the day preferably 3 meals & 2 snacks with avoidance of simple sugars.

Encouraged low salt, low saturated fats and high fiber diet.

Page 38: dm pada anak

EXERCISE

Decreases insulin requirement in diabetic subjects by increasing both sensitivity of muscle cells to insulin & glucose utilization.

It can precipitate hypoglycemia in the unprepared diabetic patient.

It may worsen pre-existing diabetic retinopathy.

Page 39: dm pada anak

MONITORING

Compliance (check records) HBG tests HbA1 every 2 months Insulin & meal plan Growth & development Well being & life style School & hobbies

Page 40: dm pada anak

ADVANCES IN MONITORING

Smaller & accurate meters for intermittent BG monitoring

Glucowatch continuous monitoring using reverse iontophoresis to measure interstitial fluid glucose every 20 minutes

Glucosensor that measures s/c capillary BG every 5 minutes

Implantable sensor with high & low BG alarm

Page 41: dm pada anak

ADVANCES IN MANAGEMENT

Better understanding of diabetes allows more rational approach to therapy.

Primary prevention could be possible if the triggering factors are identified.

The DCCT studies proves beyond doubt that chronic diabetic complication can be controlled or prevented by strict glycemic control.

Page 42: dm pada anak

TREATMENT MADE EASY

Insulin pens & new delivery products

Handy insulin pumps fine micro needles Simple accurate glucometers Free educational material computer programs for

comprehensive management & monitoring

Page 43: dm pada anak

TELECARE SYSTEMS

IT has improved diabetes care Internet sites for education &

support Web-based systems for telecare

are now available. The patient feeds his HBGM data and get the physician, nurse & dietician advice on the required modification to diet & insulin treatment.

Page 44: dm pada anak

PITFALLS OF MANAGEMENT

Delayed diagnosis of IDDM

The honey-moon period

Detection & treatment of NIDDY

Problems with diagnosis & treatment of DKA & hypoglycemia

Somogi’s effect (dawn phenomenon) may go unrecognized.

Page 45: dm pada anak

FUTURE PROMISES The cure for IDDM is successful islet

cell transplantation, which will be

available in the near future.

Primary prevention by a vaccine or

drug will be offered to at risk subjects

identified by genetic studies.

Gene modulation therapy for

susceptible subjects is a promising

preventive measure.

Page 46: dm pada anak

Pancreas & Islet Cell Transplantation

Pancreas transplants are usually given to diabetics with end stage renal disease.

Islet cell transplants, the ultimate treatment of type 1 diabetes is under trial in many centers in the US & Europe with encouraging results but graft rejection & recurrence of autoimmunity are serious limitations.

Page 47: dm pada anak

IMMUNE MODULATION

Immunosuppressive therapy forNewly diagnosedProlonged the honey moonFor high risk children

Immune modulating drugsNicotinamidemycophenolate

Page 48: dm pada anak

GENE THERAPY

Blocks the immunologic attack against islet-cells by DNA-plasmids encoding self antigen.

Gene encode cytokine inhibitors.

Modifying gene expressed islet-cell antigens like GAD.

Page 49: dm pada anak

PREDICTION OF DIABETES

Sensitive & specific immunologic markersGAD AntibodiesGLIMA antibodiesIA-2 antibodies

Sensitive genetic markers• HLA haplotypes• DQ molecular markers

Page 50: dm pada anak

PREVENTION OF DIABETES

Primary prevention• Identification of diabetes gene• Tampering with the immune system• Elimination of environmental factor

Secondary prevention• Immunosuppressive therapy

Tertiary prevention• Tight metabolic control & good

monitoring

Page 51: dm pada anak

Dreams are the seedlings of realities